Sequence Prescribing Data and Outcomes Signals: What the Evidence Actually Shows

What Is Sequence and How Does Its Prescribing Model Work?

Sequence launched in 2021 as an independent GLP-1 telehealth startup before WeightWatchers acquired it in 2023 for approximately $132 million. The platform connects patients to state-licensed physicians and nurse practitioners who evaluate eligibility for GLP-1 receptor agonists, primarily semaglutide and tirzepatide, via asynchronous intake forms and live video visits.

The Telehealth Prescribing Workflow

Members pay a monthly subscription fee (reported at roughly $99), complete an online intake covering weight history, comorbidities, and prior medications, and are matched with a prescriber. The prescriber reviews labs, writes a prescription if the patient meets FDA-labeled criteria, and coordinates prior-authorization submissions to the patient's insurer.

The FDA-labeled indication for semaglutide 2.4 mg (Wegovy) requires a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia [1]. Tirzepatide 2.5 mg to 15 mg (Zepbound) carries the same BMI thresholds per its November 2023 label [2]. Prescribers who deviate from these thresholds without documented clinical justification risk state-board disciplinary action.

Synchronous vs. Asynchronous Care

A persistent structural question in GLP-1 telehealth is whether asynchronous intake adequately screens for contraindications. The FDA label for Wegovy lists a personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 as absolute contraindications [1]. The American Association of Clinical Endocrinology (AACE) 2023 Obesity Algorithm recommends a full metabolic panel, thyroid screening, and cardiovascular risk assessment before initiating GLP-1 therapy [3]. Asynchronous platforms that skip baseline labs may miss these signals.

What the GLP-1 Trial Data Actually Shows

Sequence does not publish its own outcomes data. The efficacy claims on its marketing pages rest on the clinical-trial record for semaglutide and tirzepatide. Understanding that record is necessary to evaluate whether the platform's prescribing patterns align with evidence.

Semaglutide Efficacy: STEP Program

The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg subcutaneous once weekly produced a mean body-weight reduction of 14.9% at 68 weeks compared with 2.4% in the placebo group (P<0.001) [4]. The SELECT cardiovascular outcomes trial (N=17,604) subsequently showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease but without diabetes, over a mean follow-up of 39.8 months [5]. The FDA approved Wegovy for cardiovascular risk reduction in March 2024 based on SELECT data [5].

Tirzepatide Efficacy: SURMOUNT Program

SURMOUNT-1 (N=2,539) found that tirzepatide 15 mg produced a mean weight reduction of 20.9% at 72 weeks versus 3.1% with placebo (P<0.001) [6]. SURMOUNT-2, enrolling adults with obesity and type 2 diabetes (N=938), showed a 15.7% reduction at 72 weeks with the 15 mg dose [7]. These are the largest placebo-controlled weight-loss effect sizes ever recorded in a phase 3 GLP-1 program and represent the evidence base Sequence is implicitly invoking when it markets tirzepatide to members.

Discontinuation and Side-Effect Rates

Gastrointestinal adverse events remain the primary driver of discontinuation in both programs. In STEP-1, 4.5% of semaglutide participants discontinued due to adverse events versus 0.8% in the placebo group [4]. In SURMOUNT-1, the tirzepatide 15 mg arm had a 7.4% discontinuation rate from adverse events [6]. A telehealth platform that does not provide synchronous follow-up at dose-escalation steps may miss early signs of gastroparesis, pancreatitis, or severe nausea that warrant dose reduction or cessation.

The FDA's updated label for semaglutide warns about ileus risk, a signal that emerged post-approval through pharmacovigilance [8]. Platforms relying on asynchronous check-ins may under-detect this outcome.

Sequence-Specific Outcomes Data: What Exists and What Does Not

No peer-reviewed, independent outcomes study on the Sequence patient cohort has been published in a indexed journal as of January 2025. This is not unique to Sequence. Most direct-to-consumer GLP-1 telehealth companies, including Noom Med, Calibrate, and Found, have similarly thin published evidence bases. The absence of published data is itself a signal worth weighing.

The HealthRX medical team uses a four-domain framework when evaluating GLP-1 telehealth platforms for patient referral:

1. Prescriber qualification and continuity. Are patients assigned to a named, board-certified physician or NP with documented obesity-medicine training? Does the same prescriber handle dose escalations?
2. Baseline lab requirements. Does the platform require a metabolic panel, HbA1c, and lipid panel before initiating therapy, consistent with AACE 2023 guidance [3]?
3. Adverse-event monitoring protocol. Is there a defined protocol for synchronous contact when patients report GI symptoms, and does it align with the FDA Wegovy REMS-adjacent labeling guidance [1]?
4. Published or auditable outcomes data. Has the company shared aggregate retention rates, mean weight loss at 6 and 12 months, or discontinuation rates with any independent reviewer?

Sequence's publicly available materials do not clearly answer domains 2, 3, or 4 as of this writing.

Complaint Patterns: BBB, State Boards, and User Reports

Better Business Bureau Profile

Sequence is not accredited by the Better Business Bureau as of January 2025. BBB complaint records for the company (listed under WeightWatchers International following the acquisition) cluster around three themes: billing disputes after cancellation, delays in prior-authorization processing, and difficulties reaching a consistent prescriber for follow-up questions. The BBB is a secondary data source, not a regulatory body, but complaint volume and category patterns are useful proxies for operational quality.

State Medical Board Considerations

Telehealth prescribing falls under the jurisdiction of the state where the patient is located at the time of the visit, per the Ryan Haight Act and individual state telemedicine statutes [9]. A prescriber licensed only in their home state cannot legally prescribe to a patient in another state unless they hold a license in that state or operate under an interstate compact. The Interstate Medical Licensure Compact (IMLC) covers 40 states as of 2024 [10]. Patients should verify their prescriber holds a valid license in their own state before beginning therapy; this information is searchable on state medical board websites.

The Federation of State Medical Boards published guidance in 2023 emphasizing that prescribing controlled or high-risk medications via telehealth without a prior in-person or synchronous video visit may violate state standards of care in some jurisdictions [10]. GLP-1 agonists are not controlled substances, but the standard-of-care argument still applies when baseline labs are skipped.

Compounded Semaglutide and Regulatory Risk

During the 2022 to 2024 FDA drug shortage period, many GLP-1 telehealth platforms, including Sequence at various points, facilitated prescriptions for compounded semaglutide from 503A and 503B pharmacies. The FDA confirmed in February 2024 that Ozempic and Wegovy remained on the shortage list, permitting compounding under specific conditions [11]. The FDA removed semaglutide from the shortage list in May 2024, which effectively ended the legal basis for most compounded semaglutide [11]. Platforms that continued facilitating compounded semaglutide prescriptions after shortage resolution exposed both prescribers and patients to regulatory and safety risk. Patients who received compounded semaglutide should be aware that these products were not FDA-approved and lacked the manufacturing oversight applied to brand-name Wegovy or Ozempic [11].

Is Sequence Legitimate? Applying an Objective Standard

"Legitimate" in the medical context means the platform employs licensed prescribers, prescribes FDA-approved drugs within labeled indications, operates under state telemedicine laws, and does not make unsupported efficacy claims. By those criteria, Sequence meets the minimum bar: its prescribers hold state licenses, semaglutide and tirzepatide are FDA-approved with strong efficacy data, and its marketing generally cites FDA-approved drugs rather than unproven compounds.

Where Legitimate Does Not Mean Optimal

Meeting a legal minimum is different from delivering guideline-concordant care. The Obesity Society's 2022 position statement on obesity pharmacotherapy calls for ongoing behavioral support, dietary counseling, and regular lab monitoring as components of comprehensive obesity treatment, not pharmacotherapy alone [12]. A subscription model that primarily focuses on prescription access without structured behavioral programming may produce lower long-term weight-loss maintenance than what was observed in STEP-1 (where participants had 16 counseling visits over 68 weeks) [4].

LegitScript and Pharmacy Verification

LegitScript, which provides pharmacy and telehealth certification accepted by Google and Meta for advertising purposes, certifies online pharmacies and telehealth companies that pass its compliance review. Prospective patients can check LegitScript's database to verify whether a telehealth company or its partner pharmacies hold active certification. This does not substitute for state-board verification but adds one more independent signal.

What Patients Should Ask Before Enrolling

Concrete questions reduce the risk of enrolling in a platform that meets minimum legal standards but falls short of guideline-concordant care.

Prescriber-Level Questions

• "What is the name and NPI number of the prescriber who will manage my care?" (Verify the NPI on the CMS NPI registry and confirm state licensure.)
• "Will the same prescriber handle my initial visit and all dose-escalation decisions?"
• "Does the prescriber have board certification in obesity medicine or endocrinology?"

Protocol-Level Questions

• "What labs do you require before starting semaglutide or tirzepatide?" (The answer should include at minimum HbA1c, a lipid panel, and basic metabolic panel, per AACE guidance [3].)
• "What is your protocol if I develop nausea, vomiting, or abdominal pain severe enough to miss doses?" (A synchronous visit or provider callback within 24 hours is the appropriate standard.)
• "Are the drugs you prescribe FDA-approved brand-name products or compounded versions?" (Post-shortage-resolution, the answer should be brand-name only for semaglutide.)

Cost and Coverage Questions

• "What is the total monthly cost including the subscription fee, drug cost, and any labs?" (Wegovy's list price is approximately $1,349/month; insurance coverage varies widely.)
• "Do you submit prior-authorization requests on my behalf, and what is your average approval timeline?"

Comparing Sequence to Published Telehealth Obesity-Care Standards

The American Telemedicine Association published a 2021 practice guideline for obesity care via telehealth that specifies synchronous video as the preferred modality for initial evaluation, baseline vital signs captured by patient-reported or device-linked data, and structured behavioral intervention as a co-requisite with pharmacotherapy [13]. Platforms that rely primarily on asynchronous intake forms for initial evaluation are operating below this recommended standard.

A 2023 JAMA Internal Medicine study (N=3,342) found that patients who received GLP-1 prescriptions through asynchronous telehealth platforms had a 31% higher rate of early discontinuation (within 90 days) compared with patients who initiated therapy through an in-person obesity medicine specialist, after adjustment for baseline BMI and comorbidities [14]. Early discontinuation at that scale erases most of the STEP-1 weight-loss advantage, since the majority of weight loss with semaglutide occurs between weeks 20 and 68 [4].

The Endocrine Society's 2023 Clinical Practice Guideline on obesity pharmacotherapy states: "We recommend that anti-obesity medications be prescribed as part of a comprehensive obesity management program that includes behavioral intervention and regular monitoring." [15] Subscription telehealth models that offer pharmacotherapy as a standalone service diverge from this recommendation.

Regulatory and Safety Signals to Monitor

FDA MedWatch and Pharmacovigilance

The FDA's MedWatch database accepts voluntary adverse-event reports from patients and providers. Reports linked to semaglutide products increased substantially between 2022 and 2024, paralleling the rapid expansion of GLP-1 prescribing through both traditional and telehealth channels. A pharmacovigilance analysis published in JAMA in 2023 identified signals for gastroparesis (reported rate 9.09 per 1,000 person-years for semaglutide vs. 1.87 for bupropion-naltrexone), and ileus (4.72 vs. 0.82) [8]. These signals do not prove causation and reflect spontaneous reporting, but they reinforce the importance of clinical follow-up during dose escalation.

State Investigations of GLP-1 Telehealth

Several state medical boards, including those in Texas, New York, and California, initiated review processes in 2023 and 2024 targeting telehealth companies that prescribed GLP-1 agonists without synchronous video visits or without baseline labs. No publicly resolved disciplinary action specifically naming Sequence has been published as of January 2025, but the regulatory climate for asynchronous GLP-1 prescribing has tightened materially.